Hepatoblastoma — Trials

Hepatoblastoma — Trials · CancerIndex

Clinical trials

Registered studies

61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 11
Ph III recruiting: 1
Growth YoY: —
Industry share: 12%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03210714	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	active not recruiting	Phase 2	20	National Cancer Institute (NCI)NIH	2	Sep 22, 2026	clinicaltrials
NCT03698994	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	active not recruiting	Phase 2	20	National Cancer Institute (NCI)NIH